Last reviewed · How we verify
treatment of physician's choice
treatment of physician's choice is a Small molecule drug developed by Peking Union Medical College Hospital. It is currently in Phase 3 development for Treatment of physician's choice. Also known as: any drug or regimen approved in metastatic cancer.
The drug works by allowing the physician to choose a treatment.
The drug works by allowing the physician to choose a treatment. Used for Treatment of physician's choice.
At a glance
| Generic name | treatment of physician's choice |
|---|---|
| Also known as | any drug or regimen approved in metastatic cancer |
| Sponsor | Peking Union Medical College Hospital |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
This allows the physician to select the most appropriate treatment for the patient's condition.
Approved indications
- Treatment of physician's choice
Common side effects
Key clinical trials
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) (PHASE3)
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (PHASE3)
- A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) (PHASE3)
- Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial (PHASE3)
- Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (PHASE2)
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- treatment of physician's choice CI brief — competitive landscape report
- treatment of physician's choice updates RSS · CI watch RSS
- Peking Union Medical College Hospital portfolio CI
Frequently asked questions about treatment of physician's choice
What is treatment of physician's choice?
How does treatment of physician's choice work?
What is treatment of physician's choice used for?
Who makes treatment of physician's choice?
Is treatment of physician's choice also known as anything else?
What development phase is treatment of physician's choice in?
Related
- Manufacturer: Peking Union Medical College Hospital — full pipeline
- Indication: Drugs for Treatment of physician's choice
- Also known as: any drug or regimen approved in metastatic cancer
- Compare: treatment of physician's choice vs similar drugs
- Pricing: treatment of physician's choice cost, discount & access